What is it about?
A cross-sectional analysis was performed to analyse the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in patients treated with TNF-alpha blockers for psoriasis or psoriatic arthritis (PsA) and compare it in control subjects treated with conventional antipsoriatic drugs.
Featured Image
Why is it important?
A higher prevalence of MGUS among patients with psoriasis may result from chronic immune dysregulation. We found no evidence of increased overall prevalence of MGUS in patients taking TNF-alpha inhibitors with respect to individuals taking conventional drugs. Proportions of patients with MGUS were similar between the two groups which were investigated and even higher in the control group.
Perspectives
No indications about the risk of progression to multiple myeloma in patients with MGUS treated with TNF-blockers can be drawn. Longitudinal studies could confirm our observations as well as the significance of polyclonal gammopathy in patients taking TNF-alpha inhibitors.
Dr Vito Di Lernia
Arcispedale S. Maria Nuova
Read the Original
This page is a summary of: Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study, Journal of the European Academy of Dermatology and Venereology, June 2014, Wiley,
DOI: 10.1111/jdv.12565.
You can read the full text:
Contributors
The following have contributed to this page
